Baseline demographic and clinical characteristics after propensity score matching
| Characteristics . | Total, n (%) . | DOAC, n (%) . | Anticoagulant group . | P value . | |
|---|---|---|---|---|---|
| LMWH, n (%) . | Warfarin, n (%) . | ||||
| N = 4875 . | n = 1625 . | n = 1625 . | n = 1625 . | ||
| Age, median (IQR), y | 75 (70-81) | 75 (71-81) | 75 (70-80) | 75 (70-81) | .65 |
| Sex | |||||
| Male | 2034 (42) | 667 (41) | 679 (42) | 664 (41) | .75 |
| Female | 2841 (58) | 958 (59) | 946 (58) | 961 (59) | |
| Race | |||||
| White | 4194 (86) | 1386 (85) | 1393 (86) | 1415 (87) | .68 |
| Black | 420 (9) | 146 (9) | 141 (9) | 133 (8) | |
| Other | 244 (5) | 86 (5) | 84 (5) | 74 (5) | |
| Type of VTE | |||||
| DVT without PE | 2822 (58) | 938 (58) | 926 (57) | 958 (59) | .52 |
| PE with/without DVT | 2053 (42) | 687 (42) | 699 (43) | 667 (41) | |
| Time from cancer to VTE, mo | |||||
| Median (IQR) | 4.7 (1.2-17.5) | 5.1 (1.2-21.0) | 4.5 (1.2-15.7) | 4.7 (1.2-16.6) | |
| ≤3 | 1886 (39) | 631 (39) | 627 (39) | 628 (39) | >.99 |
| >3 | 2989 (61) | 994 (61) | 998 (61) | 997 (61) | |
| DOAC | |||||
| Apixaban | 204 (4) | 204 (13) | — | — | N/A |
| Rivaroxaban | 1352 (28) | 1352 (83) | — | — | |
| Edoxaban | 69 (1) | 69 (4) | — | — | |
| LMWH | |||||
| Enoxaparin | 1588 (33) | — | 1588 (98) | — | N/A |
| Dalteparin or fondaparinux | 37 (1) | — | 37 (2) | — | |
| Primary cancer site | |||||
| Gastric | 158 (3) | 59 (4) | 51 (3) | 48 (4) | .97 |
| Colorectal | 1328 (27) | 446 (27) | 448 (28) | 434 (27) | |
| Pancreatic | 631 (13) | 207 (13) | 200 (12) | 224 (14) | |
| Lung | 2257 (46) | 742 (46) | 761 (47) | 754 (46) | |
| Ovarian | 360 (7) | 124 (8) | 117 (7) | 119 (7) | |
| Brain | 141 (3) | 47 (3) | 48 (3) | 46 (3) | |
| Stage | |||||
| I-II | 1623 (33) | 539 (33) | 539 (33) | 545 (34) | >.99 |
| III | 1185 (24) | 394 (24) | 394 (24) | 397 (24) | |
| IV | 1636 (34) | 551 (34) | 551 (34) | 534 (33) | |
| Not applicable | 194 (4) | 63 (4) | 63 (4) | 68 (4) | |
| Unknown | 237 (5) | 78 (5) | 78 (5) | 81 (5) | |
| Receipt of systemic anticancer therapy∗ | 2071 (42) | 679 (42) | 693 (43) | 699 (43) | .77 |
| Elixhauser comorbidity index, median (range) | 3 (0-14) | 3 (0-10) | 3 (0-14) | 3 (0-11) | <.001 |
| Cardiac comorbidities | |||||
| Tobacco use | 2529 (52) | 843 (52) | 833 (51) | 853 (52) | .78 |
| Hypertension | 4129 (85) | 1377 (85) | 1376 (85) | 1376 (85) | >.99 |
| Atrial fibrillation/flutter | 1401 (29) | 485 (30) | 457 (28) | 459 (28) | .49 |
| Congestive heart failure | 1501 (31) | 512 (32) | 488 (30) | 501 (31) | .66 |
| Peripheral artery disease | 1462 (30) | 488 (30) | 482 (30) | 492 (30) | .93 |
| Coronary artery disease | 2131 (44) | 706 (43) | 708 (44) | 717 (44) | .92 |
| Cerebrovascular disease | 1191 (24) | 406 (25) | 407 (25) | 378 (23) | .41 |
| Diabetes mellitus | 2065 (42) | 695 (43) | 691 (43) | 679 (42) | .84 |
| Previous stroke or TIA | 883 (18) | 307 (19) | 280 (17) | 296 (18) | .47 |
| Previous myocardial infarction | 451 (9) | 161 (10) | 145 (9) | 145 (9) | .54 |
| Previous systemic thromboembolism | 233 (5) | 76 (5) | 80 (5) | 77 (5) | .96 |
| Any previous ATE | 1300 (27) | 454 (28) | 424 (26) | 422 (26) | .36 |
| Statin use | 274 (6) | 92 (6) | 96 (6) | 86 (5) | .67 |
| Atorvastatin | 179 (4) | 53 (3) | 63 (4) | 63 (4) | |
| Fluvastatin | 1 (0) | 1 (0) | — | — | |
| Lovastatin | 2 (0) | 1 (0) | 1 (0) | — | |
| Pravastatin | 92 (2) | 37 (2) | 32 (2) | 23 (1) | |
| Characteristics . | Total, n (%) . | DOAC, n (%) . | Anticoagulant group . | P value . | |
|---|---|---|---|---|---|
| LMWH, n (%) . | Warfarin, n (%) . | ||||
| N = 4875 . | n = 1625 . | n = 1625 . | n = 1625 . | ||
| Age, median (IQR), y | 75 (70-81) | 75 (71-81) | 75 (70-80) | 75 (70-81) | .65 |
| Sex | |||||
| Male | 2034 (42) | 667 (41) | 679 (42) | 664 (41) | .75 |
| Female | 2841 (58) | 958 (59) | 946 (58) | 961 (59) | |
| Race | |||||
| White | 4194 (86) | 1386 (85) | 1393 (86) | 1415 (87) | .68 |
| Black | 420 (9) | 146 (9) | 141 (9) | 133 (8) | |
| Other | 244 (5) | 86 (5) | 84 (5) | 74 (5) | |
| Type of VTE | |||||
| DVT without PE | 2822 (58) | 938 (58) | 926 (57) | 958 (59) | .52 |
| PE with/without DVT | 2053 (42) | 687 (42) | 699 (43) | 667 (41) | |
| Time from cancer to VTE, mo | |||||
| Median (IQR) | 4.7 (1.2-17.5) | 5.1 (1.2-21.0) | 4.5 (1.2-15.7) | 4.7 (1.2-16.6) | |
| ≤3 | 1886 (39) | 631 (39) | 627 (39) | 628 (39) | >.99 |
| >3 | 2989 (61) | 994 (61) | 998 (61) | 997 (61) | |
| DOAC | |||||
| Apixaban | 204 (4) | 204 (13) | — | — | N/A |
| Rivaroxaban | 1352 (28) | 1352 (83) | — | — | |
| Edoxaban | 69 (1) | 69 (4) | — | — | |
| LMWH | |||||
| Enoxaparin | 1588 (33) | — | 1588 (98) | — | N/A |
| Dalteparin or fondaparinux | 37 (1) | — | 37 (2) | — | |
| Primary cancer site | |||||
| Gastric | 158 (3) | 59 (4) | 51 (3) | 48 (4) | .97 |
| Colorectal | 1328 (27) | 446 (27) | 448 (28) | 434 (27) | |
| Pancreatic | 631 (13) | 207 (13) | 200 (12) | 224 (14) | |
| Lung | 2257 (46) | 742 (46) | 761 (47) | 754 (46) | |
| Ovarian | 360 (7) | 124 (8) | 117 (7) | 119 (7) | |
| Brain | 141 (3) | 47 (3) | 48 (3) | 46 (3) | |
| Stage | |||||
| I-II | 1623 (33) | 539 (33) | 539 (33) | 545 (34) | >.99 |
| III | 1185 (24) | 394 (24) | 394 (24) | 397 (24) | |
| IV | 1636 (34) | 551 (34) | 551 (34) | 534 (33) | |
| Not applicable | 194 (4) | 63 (4) | 63 (4) | 68 (4) | |
| Unknown | 237 (5) | 78 (5) | 78 (5) | 81 (5) | |
| Receipt of systemic anticancer therapy∗ | 2071 (42) | 679 (42) | 693 (43) | 699 (43) | .77 |
| Elixhauser comorbidity index, median (range) | 3 (0-14) | 3 (0-10) | 3 (0-14) | 3 (0-11) | <.001 |
| Cardiac comorbidities | |||||
| Tobacco use | 2529 (52) | 843 (52) | 833 (51) | 853 (52) | .78 |
| Hypertension | 4129 (85) | 1377 (85) | 1376 (85) | 1376 (85) | >.99 |
| Atrial fibrillation/flutter | 1401 (29) | 485 (30) | 457 (28) | 459 (28) | .49 |
| Congestive heart failure | 1501 (31) | 512 (32) | 488 (30) | 501 (31) | .66 |
| Peripheral artery disease | 1462 (30) | 488 (30) | 482 (30) | 492 (30) | .93 |
| Coronary artery disease | 2131 (44) | 706 (43) | 708 (44) | 717 (44) | .92 |
| Cerebrovascular disease | 1191 (24) | 406 (25) | 407 (25) | 378 (23) | .41 |
| Diabetes mellitus | 2065 (42) | 695 (43) | 691 (43) | 679 (42) | .84 |
| Previous stroke or TIA | 883 (18) | 307 (19) | 280 (17) | 296 (18) | .47 |
| Previous myocardial infarction | 451 (9) | 161 (10) | 145 (9) | 145 (9) | .54 |
| Previous systemic thromboembolism | 233 (5) | 76 (5) | 80 (5) | 77 (5) | .96 |
| Any previous ATE | 1300 (27) | 454 (28) | 424 (26) | 422 (26) | .36 |
| Statin use | 274 (6) | 92 (6) | 96 (6) | 86 (5) | .67 |
| Atorvastatin | 179 (4) | 53 (3) | 63 (4) | 63 (4) | |
| Fluvastatin | 1 (0) | 1 (0) | — | — | |
| Lovastatin | 2 (0) | 1 (0) | 1 (0) | — | |
| Pravastatin | 92 (2) | 37 (2) | 32 (2) | 23 (1) | |
IQR, interquartile range; N/A, not applicable; TIA, transient ischemic attack.
Within 3 months of study index.